Stifel Financial
ACAD icon

Stifel Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

Stifel Financial’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$511K Buy
20,214
+8,066
+66% +$177K ﹤0.01% 2956
2026
Q1 		$270K Sell
12,148
-692
-5% -$16.5K ﹤0.01% 3253
2025
Q4 		$343K Buy
+12,840
New +$307K ﹤0.01% 3071
2020
Q3 		– Sell
-21,804
Closed -$1.06M – 2874
2020
Q2 		$1.06M Buy
21,804
+766
+4% +$36.8K ﹤0.01% 1517
2020
Q1 		$886K Sell
21,038
-6,351
-23% -$262K ﹤0.01% 1515
2019
Q4 		$1.17M Buy
27,389
+20,964
+326% +$912K ﹤0.01% 1707
2019
Q3 		$227K Buy
+6,425
New +$195K ﹤0.01% 2589
2018
Q4 		– Sell
-11,656
Closed -$244K – 2657
2018
Q3 		$244K Buy
+11,656
New +$183K ﹤0.01% 2472
2017
Q4 		– Sell
-7,373
Closed -$279K – 2647
2017
Q3 		$279K Sell
7,373
-225
-3% -$7.32K ﹤0.01% 2189
2017
Q2 		$209K Sell
7,598
-1,110
-13% -$33.1K ﹤0.01% 2321
2017
Q1 		$302K Buy
8,708
+260
+3% +$9.18K ﹤0.01% 2085
2016
Q4 		$242K Sell
8,448
-2,150
-20% -$56.9K ﹤0.01% 2166
2016
Q3 		$334K Sell
10,598
-468
-4% -$15.9K ﹤0.01% 1935
2016
Q2 		$359K Buy
+11,066
New +$370K ﹤0.01% 1945

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Stifel Financial's ACAD Position: Q2 2026 in Review

Stifel Financial increased its Acadia Pharmaceuticals (ACAD) stake by 66% in Q2 2026, buying an estimated $177K and bringing the position to 20,214 shares worth $511K. The position accounts for ﹤0.01% of the portfolio, ranked #2956.

Stifel Financial first reported a position in ACAD in Q2 2016 and has held it in 14 quarters since. The position peaked at $1.17M in Q4 2019. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Stifel Financial held 20,214 shares of Acadia Pharmaceuticals worth $511K as of Q2 2026.
  • Stifel Financial bought 8,066 Acadia Pharmaceuticals shares in Q2 2026, an estimated $177K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #2956 holding.
  • Stifel Financial first reported a position in Acadia Pharmaceuticals in Q2 2016 and has held it in 14 quarters since.
  • Stifel Financial's Acadia Pharmaceuticals position peaked at $1.17M in Q4 2019.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.